nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—NME1—peripheral nervous system neoplasm	0.041	0.0675	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNA signaling—IFNB1—peripheral nervous system neoplasm	0.0339	0.0557	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNG signaling—PTPN11—peripheral nervous system neoplasm	0.0313	0.0515	CbGpPWpGaD
Tiludronate—ATP6V1A—ganglion—peripheral nervous system neoplasm	0.0226	0.264	CbGeAlD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—NTRK2—peripheral nervous system neoplasm	0.0225	0.037	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—NCAM1—peripheral nervous system neoplasm	0.0198	0.0325	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNA signaling—PTPN11—peripheral nervous system neoplasm	0.0191	0.0314	CbGpPWpGaD
Tiludronate—PTPN1—trigeminal ganglion—peripheral nervous system neoplasm	0.0186	0.217	CbGeAlD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—HGF—peripheral nervous system neoplasm	0.0185	0.0305	CbGpPWpGaD
Tiludronate—PTPN1—IGF1 pathway—PTPN11—peripheral nervous system neoplasm	0.017	0.028	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—BDNF—peripheral nervous system neoplasm	0.0168	0.0276	CbGpPWpGaD
Tiludronate—PTPN1—Interferon alpha/beta signaling—IFNB1—peripheral nervous system neoplasm	0.0163	0.0268	CbGpPWpGaD
Tiludronate—PTPN1—N-cadherin signaling events—PTPN11—peripheral nervous system neoplasm	0.0147	0.0242	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—MET—peripheral nervous system neoplasm	0.0146	0.024	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—MET—peripheral nervous system neoplasm	0.0126	0.0208	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Pathway—PTPN11—peripheral nervous system neoplasm	0.0123	0.0202	CbGpPWpGaD
Tiludronate—ATP6V1A—trigeminal ganglion—peripheral nervous system neoplasm	0.0111	0.13	CbGeAlD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HGF—peripheral nervous system neoplasm	0.0106	0.0175	CbGpPWpGaD
Tiludronate—ATP6V1A—parotid gland—peripheral nervous system neoplasm	0.0105	0.123	CbGeAlD
Tiludronate—ATP6V1A—brainstem—peripheral nervous system neoplasm	0.00984	0.115	CbGeAlD
Tiludronate—Bone pain—Topotecan—peripheral nervous system neoplasm	0.00967	0.0316	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—NCAM1—peripheral nervous system neoplasm	0.00966	0.0159	CbGpPWpGaD
Tiludronate—Bone pain—Isotretinoin—peripheral nervous system neoplasm	0.0096	0.0313	CcSEcCtD
Tiludronate—Bone pain—Tretinoin—peripheral nervous system neoplasm	0.0096	0.0313	CcSEcCtD
Tiludronate—PTPN1—Interferon alpha/beta signaling—PTPN11—peripheral nervous system neoplasm	0.00917	0.0151	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—PTPN11—peripheral nervous system neoplasm	0.00874	0.0144	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—peripheral nervous system neoplasm	0.0084	0.0138	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—CASP3—peripheral nervous system neoplasm	0.00838	0.0138	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—PTPN11—peripheral nervous system neoplasm	0.00818	0.0134	CbGpPWpGaD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	0.00811	0.0133	CbGpPWpGaD
Tiludronate—PTPN1—cerebellum—peripheral nervous system neoplasm	0.0081	0.0946	CbGeAlD
Tiludronate—PTPN1—Insulin Signaling—SLC2A1—peripheral nervous system neoplasm	0.00798	0.0131	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—PTPN11—peripheral nervous system neoplasm	0.00776	0.0128	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—IFNB1—peripheral nervous system neoplasm	0.00758	0.0125	CbGpPWpGaD
Tiludronate—PTPN1—IGF1 pathway—HRAS—peripheral nervous system neoplasm	0.00749	0.0123	CbGpPWpGaD
Tiludronate—Bone pain—Alitretinoin—peripheral nervous system neoplasm	0.00727	0.0237	CcSEcCtD
Tiludronate—PTPN1—Integrin alphaIIb beta3 signaling—AKT1—peripheral nervous system neoplasm	0.00719	0.0118	CbGpPWpGaD
Tiludronate—Bone pain—Vincristine—peripheral nervous system neoplasm	0.00701	0.0229	CcSEcCtD
Tiludronate—PTPN1—IGF1 pathway—AKT1—peripheral nervous system neoplasm	0.00661	0.0109	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—ERBB2—peripheral nervous system neoplasm	0.00646	0.0106	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—NCAM1—peripheral nervous system neoplasm	0.00645	0.0106	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—PTPN11—peripheral nervous system neoplasm	0.00577	0.00949	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.00567	0.00932	CbGpPWpGaD
Tiludronate—PTPN1—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.00559	0.00919	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—PTPN11—peripheral nervous system neoplasm	0.00543	0.00894	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Pathway—HRAS—peripheral nervous system neoplasm	0.00541	0.0089	CbGpPWpGaD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00519	0.00854	CbGpPWpGaD
Tiludronate—PTPN1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—peripheral nervous system neoplasm	0.00514	0.00845	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IFNB1—peripheral nervous system neoplasm	0.00506	0.00832	CbGpPWpGaD
Tiludronate—ATP6V1A—cerebellum—peripheral nervous system neoplasm	0.00485	0.0567	CbGeAlD
Tiludronate—PTPN1—Insulin Pathway—AKT1—peripheral nervous system neoplasm	0.00478	0.00786	CbGpPWpGaD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.00472	0.00776	CbGpPWpGaD
Tiludronate—Rhinitis—Topotecan—peripheral nervous system neoplasm	0.00467	0.0152	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—PTPN11—peripheral nervous system neoplasm	0.00446	0.00733	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—PTPN11—peripheral nervous system neoplasm	0.00427	0.00702	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—AKT1—peripheral nervous system neoplasm	0.00426	0.007	CbGpPWpGaD
Tiludronate—Back pain—Topotecan—peripheral nervous system neoplasm	0.00392	0.0128	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HGF—peripheral nervous system neoplasm	0.00391	0.00642	CbGpPWpGaD
Tiludronate—Back pain—Isotretinoin—peripheral nervous system neoplasm	0.00389	0.0127	CcSEcCtD
Tiludronate—Back pain—Tretinoin—peripheral nervous system neoplasm	0.00389	0.0127	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.0036	0.00591	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—NRAS—peripheral nervous system neoplasm	0.00347	0.0057	CbGpPWpGaD
Tiludronate—Myalgia—Topotecan—peripheral nervous system neoplasm	0.00345	0.0113	CcSEcCtD
Tiludronate—Arthralgia—Topotecan—peripheral nervous system neoplasm	0.00345	0.0113	CcSEcCtD
Tiludronate—Myalgia—Tretinoin—peripheral nervous system neoplasm	0.00342	0.0112	CcSEcCtD
Tiludronate—Arthralgia—Isotretinoin—peripheral nervous system neoplasm	0.00342	0.0112	CcSEcCtD
Tiludronate—Myalgia—Isotretinoin—peripheral nervous system neoplasm	0.00342	0.0112	CcSEcCtD
Tiludronate—Arthralgia—Tretinoin—peripheral nervous system neoplasm	0.00342	0.0112	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—peripheral nervous system neoplasm	0.00342	0.00562	CbGpPWpGaD
Tiludronate—Myalgia—Melphalan—peripheral nervous system neoplasm	0.00338	0.011	CcSEcCtD
Tiludronate—PTPN1—Immune System—CD55—peripheral nervous system neoplasm	0.00327	0.00538	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—NRAS—peripheral nervous system neoplasm	0.00327	0.00537	CbGpPWpGaD
Tiludronate—Bone pain—Epirubicin—peripheral nervous system neoplasm	0.00318	0.0104	CcSEcCtD
Tiludronate—PTPN1—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.00318	0.00522	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.00315	0.00518	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—GNS—peripheral nervous system neoplasm	0.00315	0.00518	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—MYC—peripheral nervous system neoplasm	0.00304	0.005	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—peripheral nervous system neoplasm	0.00302	0.00496	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.00301	0.00983	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.00299	0.00975	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.00299	0.00975	CcSEcCtD
Tiludronate—Influenza like illness—Epirubicin—peripheral nervous system neoplasm	0.00296	0.00966	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.00295	0.00963	CcSEcCtD
Tiludronate—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.00295	0.00962	CcSEcCtD
Tiludronate—Bone pain—Doxorubicin—peripheral nervous system neoplasm	0.00294	0.00961	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—KNG1—peripheral nervous system neoplasm	0.00292	0.0048	CbGpPWpGaD
Tiludronate—Dyspepsia—Topotecan—peripheral nervous system neoplasm	0.00291	0.0095	CcSEcCtD
Tiludronate—Dyspepsia—Tretinoin—peripheral nervous system neoplasm	0.00289	0.00942	CcSEcCtD
Tiludronate—Dyspepsia—Isotretinoin—peripheral nervous system neoplasm	0.00289	0.00942	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—PTPN11—peripheral nervous system neoplasm	0.00285	0.00469	CbGpPWpGaD
Tiludronate—Dyspepsia—Melphalan—peripheral nervous system neoplasm	0.00285	0.0093	CcSEcCtD
Tiludronate—Back pain—Vincristine—peripheral nervous system neoplasm	0.00284	0.00927	CcSEcCtD
Tiludronate—Pain—Topotecan—peripheral nervous system neoplasm	0.00283	0.00923	CcSEcCtD
Tiludronate—Pain—Tretinoin—peripheral nervous system neoplasm	0.0028	0.00916	CcSEcCtD
Tiludronate—Pain—Isotretinoin—peripheral nervous system neoplasm	0.0028	0.00916	CcSEcCtD
Tiludronate—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.0028	0.00913	CcSEcCtD
Tiludronate—Pain—Melphalan—peripheral nervous system neoplasm	0.00277	0.00904	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.00275	0.00452	CbGpPWpGaD
Tiludronate—Influenza like illness—Doxorubicin—peripheral nervous system neoplasm	0.00274	0.00894	CcSEcCtD
Tiludronate—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.0027	0.00883	CcSEcCtD
Tiludronate—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00268	0.00875	CcSEcCtD
Tiludronate—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00268	0.00875	CcSEcCtD
Tiludronate—Vertigo—Vincristine—peripheral nervous system neoplasm	0.00264	0.00861	CcSEcCtD
Tiludronate—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00261	0.00853	CcSEcCtD
Tiludronate—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.00259	0.00846	CcSEcCtD
Tiludronate—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.00259	0.00846	CcSEcCtD
Tiludronate—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00259	0.00846	CcSEcCtD
Tiludronate—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00259	0.00846	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—GNAS—peripheral nervous system neoplasm	0.00255	0.0042	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—HRAS—peripheral nervous system neoplasm	0.00254	0.00417	CbGpPWpGaD
Tiludronate—Myalgia—Vincristine—peripheral nervous system neoplasm	0.0025	0.00816	CcSEcCtD
Tiludronate—PTPN1—Immune System—CD34—peripheral nervous system neoplasm	0.00248	0.00407	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00244	0.00797	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—HGF—peripheral nervous system neoplasm	0.00243	0.004	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	0.00239	0.00393	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PPP3R1—peripheral nervous system neoplasm	0.00238	0.00392	CbGpPWpGaD
Tiludronate—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00237	0.00774	CcSEcCtD
Tiludronate—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00235	0.00768	CcSEcCtD
Tiludronate—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00235	0.00768	CcSEcCtD
Tiludronate—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00232	0.00758	CcSEcCtD
Tiludronate—Back pain—Etoposide—peripheral nervous system neoplasm	0.0023	0.00751	CcSEcCtD
Tiludronate—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00229	0.00748	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00226	0.00739	CcSEcCtD
Tiludronate—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00226	0.00738	CcSEcCtD
Tiludronate—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00224	0.00733	CcSEcCtD
Tiludronate—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00224	0.00733	CcSEcCtD
Tiludronate—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00221	0.00723	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.00221	0.00364	CbGpPWpGaD
Tiludronate—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.00221	0.00721	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.0022	0.00362	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.0022	0.00362	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—PPP3R1—peripheral nervous system neoplasm	0.0022	0.00362	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00219	0.00716	CcSEcCtD
Tiludronate—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.00219	0.00714	CcSEcCtD
Tiludronate—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00219	0.00714	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00218	0.00712	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.00217	0.00357	CbGpPWpGaD
Tiludronate—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00217	0.00708	CcSEcCtD
Tiludronate—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00217	0.00708	CcSEcCtD
Tiludronate—Vertigo—Etoposide—peripheral nervous system neoplasm	0.00214	0.00697	CcSEcCtD
Tiludronate—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00213	0.00694	CcSEcCtD
Tiludronate—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00212	0.00692	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00211	0.00348	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00211	0.00348	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—NCAM1—peripheral nervous system neoplasm	0.00211	0.00346	CbGpPWpGaD
Tiludronate—Headache—Topotecan—peripheral nervous system neoplasm	0.00207	0.00676	CcSEcCtD
Tiludronate—Headache—Tretinoin—peripheral nervous system neoplasm	0.00205	0.00671	CcSEcCtD
Tiludronate—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00205	0.00671	CcSEcCtD
Tiludronate—Pain—Vincristine—peripheral nervous system neoplasm	0.00205	0.00669	CcSEcCtD
Tiludronate—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00203	0.00664	CcSEcCtD
Tiludronate—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00196	0.00641	CcSEcCtD
Tiludronate—Nausea—Topotecan—peripheral nervous system neoplasm	0.00196	0.00641	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—HRAS—peripheral nervous system neoplasm	0.00196	0.00323	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00196	0.00639	CcSEcCtD
Tiludronate—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00195	0.00636	CcSEcCtD
Tiludronate—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00195	0.00636	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00193	0.0063	CcSEcCtD
Tiludronate—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00192	0.00628	CcSEcCtD
Tiludronate—Nausea—Melphalan—peripheral nervous system neoplasm	0.00192	0.00628	CcSEcCtD
Tiludronate—ATP6V1A—Disease—ENO2—peripheral nervous system neoplasm	0.00191	0.00314	CbGpPWpGaD
Tiludronate—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00189	0.00618	CcSEcCtD
Tiludronate—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00183	0.00599	CcSEcCtD
Tiludronate—Pain—Cisplatin—peripheral nervous system neoplasm	0.00181	0.00591	CcSEcCtD
Tiludronate—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00178	0.00582	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.00178	0.00292	CbGpPWpGaD
Tiludronate—PTPN1—Insulin Signaling—AKT1—peripheral nervous system neoplasm	0.00173	0.00285	CbGpPWpGaD
Tiludronate—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00172	0.00561	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	0.00171	0.00282	CbGpPWpGaD
Tiludronate—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.0017	0.00555	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00167	0.00275	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00167	0.00275	CbGpPWpGaD
Tiludronate—Pain—Etoposide—peripheral nervous system neoplasm	0.00166	0.00542	CcSEcCtD
Tiludronate—PTPN1—Immune System—IFNB1—peripheral nervous system neoplasm	0.00165	0.00272	CbGpPWpGaD
Tiludronate—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00164	0.00537	CcSEcCtD
Tiludronate—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00164	0.00535	CcSEcCtD
Tiludronate—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00159	0.0052	CcSEcCtD
Tiludronate—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00159	0.00518	CcSEcCtD
Tiludronate—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00158	0.00517	CcSEcCtD
Tiludronate—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00156	0.00508	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00154	0.00254	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00154	0.00254	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—SLC2A1—peripheral nervous system neoplasm	0.00154	0.00253	CbGpPWpGaD
Tiludronate—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.00153	0.00501	CcSEcCtD
Tiludronate—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00153	0.00501	CcSEcCtD
Tiludronate—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.00152	0.00496	CcSEcCtD
Tiludronate—Headache—Vincristine—peripheral nervous system neoplasm	0.0015	0.0049	CcSEcCtD
Tiludronate—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00148	0.00482	CcSEcCtD
Tiludronate—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00145	0.00473	CcSEcCtD
Tiludronate—Nausea—Vincristine—peripheral nervous system neoplasm	0.00142	0.00464	CcSEcCtD
Tiludronate—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.00142	0.00464	CcSEcCtD
Tiludronate—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00139	0.00454	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	0.00134	0.0022	CbGpPWpGaD
Tiludronate—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00133	0.00433	CcSEcCtD
Tiludronate—Back pain—Epirubicin—peripheral nervous system neoplasm	0.00129	0.00421	CcSEcCtD
Tiludronate—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00128	0.00419	CcSEcCtD
Tiludronate—PTPN1—Immune System—HGF—peripheral nervous system neoplasm	0.00128	0.0021	CbGpPWpGaD
Tiludronate—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00126	0.00411	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	0.00125	0.00206	CbGpPWpGaD
Tiludronate—Headache—Etoposide—peripheral nervous system neoplasm	0.00122	0.00397	CcSEcCtD
Tiludronate—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.0012	0.00391	CcSEcCtD
Tiludronate—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.00119	0.00389	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.00116	0.0019	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.00116	0.0019	CbGpPWpGaD
Tiludronate—Nausea—Etoposide—peripheral nervous system neoplasm	0.00115	0.00376	CcSEcCtD
Tiludronate—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00113	0.0037	CcSEcCtD
Tiludronate—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00113	0.0037	CcSEcCtD
Tiludronate—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.00111	0.00362	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—NRAS—peripheral nervous system neoplasm	0.00107	0.00176	CbGpPWpGaD
Tiludronate—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.00105	0.00343	CcSEcCtD
Tiludronate—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.00105	0.00343	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000991	0.00323	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.00099	0.00163	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.00099	0.00163	CbGpPWpGaD
Tiludronate—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000957	0.00313	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000944	0.00155	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000944	0.00155	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—PTPN11—peripheral nervous system neoplasm	0.000931	0.00153	CbGpPWpGaD
Tiludronate—Pain—Epirubicin—peripheral nervous system neoplasm	0.00093	0.00304	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000917	0.00299	CcSEcCtD
Tiludronate—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000889	0.0029	CcSEcCtD
Tiludronate—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000886	0.00289	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000866	0.00142	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000866	0.00142	CbGpPWpGaD
Tiludronate—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000861	0.00281	CcSEcCtD
Tiludronate—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00086	0.00281	CcSEcCtD
Tiludronate—ATP6V1A—Disease—PTPN11—peripheral nervous system neoplasm	0.000859	0.00141	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000823	0.00269	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—TP53—peripheral nervous system neoplasm	0.000817	0.00134	CbGpPWpGaD
Tiludronate—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000795	0.0026	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000781	0.00128	CbGpPWpGaD
Tiludronate—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.00078	0.00255	CcSEcCtD
Tiludronate—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000744	0.00243	CcSEcCtD
Tiludronate—PTPN1—Immune System—ERBB2—peripheral nervous system neoplasm	0.000736	0.00121	CbGpPWpGaD
Tiludronate—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000722	0.00236	CcSEcCtD
Tiludronate—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000719	0.00235	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—AKT1—peripheral nervous system neoplasm	0.00069	0.00113	CbGpPWpGaD
Tiludronate—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000689	0.00225	CcSEcCtD
Tiludronate—Headache—Epirubicin—peripheral nervous system neoplasm	0.000681	0.00222	CcSEcCtD
Tiludronate—ATP6V1A—Disease—ERBB2—peripheral nervous system neoplasm	0.000679	0.00112	CbGpPWpGaD
Tiludronate—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000665	0.00217	CcSEcCtD
Tiludronate—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000646	0.00211	CcSEcCtD
Tiludronate—Headache—Doxorubicin—peripheral nervous system neoplasm	0.00063	0.00206	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000602	0.00099	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000602	0.00099	CbGpPWpGaD
Tiludronate—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000598	0.00195	CcSEcCtD
Tiludronate—PTPN1—Immune System—NRAS—peripheral nervous system neoplasm	0.00056	0.00092	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—NRAS—peripheral nervous system neoplasm	0.000517	0.00085	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—MYC—peripheral nervous system neoplasm	0.000481	0.000792	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000476	0.000782	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000476	0.000782	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000432	0.00071	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000432	0.00071	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—HRAS—peripheral nervous system neoplasm	0.000409	0.000673	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—HRAS—peripheral nervous system neoplasm	0.000378	0.000622	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000362	0.000595	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000362	0.000595	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—AKT1—peripheral nervous system neoplasm	0.000362	0.000595	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000337	0.000554	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000337	0.000554	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—AKT1—peripheral nervous system neoplasm	0.000334	0.000549	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000277	0.000455	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000277	0.000455	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000265	0.000435	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000265	0.000435	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000234	0.000384	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000234	0.000384	CbGpPWpGaD
